Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

CAPVAXIVE Sales: $50 million. WINREVAIR Sales: $200 million. Gross Margin: 80.8%, an increase of 3.6 percentage points. Operating Expenses: $7.4 billion. Earnings Per Share (EPS): $1.72.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Sales of new pulmonary arterial hypertension drug, Winrevair, also missed estimates. The decline in Merck’s stock price post-earnings has left investors confused about whether to buy ...

the successful roll-out of WINREVAIR and healthy performance of its Animal Health business. Merck & Co., Inc. (NYSE:MRK) continues to progress its pipeline, advance key clinical programs and ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

GARDASIL Sales: $1.6 billion, a decrease of 18% due to lower demand in China. CAPVAXIVE Sales: $50 million. WINREVAIR Sales: $200 million. Gross Margin: 80.8%, an increase of 3.6 percentage points.

At recent prices, the stock offers a 3.7% yield. Last March, the Food and Drug Administration (FDA) approved Winrevair, a treatment for adults with pulmonary arterial hypertension. Fourth-quarter ...